ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Core Insights - ArriVent BioPharma, Inc. is presenting two significant poster presentations at the 2026 AACR Annual Meeting, focusing on innovative biopharmaceutical therapeutics for cancer treatment [1] Group 1: Firmonertinib - Firmonertinib is a novel EGFR inhibitor with high-resolution crystal structure data supporting its pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) [2] - The drug has shown early clinical evidence of activity against uncommon mutations, including exon 20 insertions and PACC variants, and is already approved in China for specific NSCLC cases [3][10] - Preclinical studies indicate firmonertinib's unique structural features enhance binding and activity against EGFR mutant proteins, demonstrating strong anti-tumor activity in various models [5][6] Group 2: ARR-002 - ARR-002, also known as AV-P138-ADC, is a dual-target tetravalent antibody drug conjugate (ADC) aimed at treating ovarian and endometrial cancers, characterized by its superior ADC potential [2][4] - The dual-target approach of ARR-002 is designed to overcome challenges faced by single-target ADCs, showing effective binding and enhanced internalization compared to single-target controls [7] - Initial preclinical data suggest ARR-002 has superior anti-tumor activity in ovarian cancer models, indicating its potential as a best-in-disease ADC [5][8] Group 3: Clinical Development - Firmonertinib is currently undergoing a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations and another for patients with EGFR PACC mutations [12] - ARR-002 is positioned for advancement towards clinical evaluation, with its development leveraging the unique characteristics of its dual-target mechanism [2][4] Group 4: Company Overview - ArriVent is dedicated to the identification, development, and commercialization of differentiated medicines to address unmet medical needs in cancer treatment [9] - The company aims to maximize the potential of its lead candidate, firmonertinib, while advancing a pipeline of novel therapeutics, including next-generation ADCs [9]